We use cookies to improve your experience and to help us understand how our site is used. You can find out more about your options on our
Cookies page.
About Cookies
Most websites these days use cookies to store and retrieve information. Some of this information might be about you,
your preferences or your device and is mostly used to help the website work in the way you expect.
This information doesn’t usually directly identify you but can give you a more personalized experience.
We will never sell any of your personally identifiable information, whether gathered using a cookie or otherwise.
We respect your right to privacy, so you can choose whether or not some cookies are enabled on our website.
However, disabling some cookies can impact your experience and the services we are able to offer. For more information see our Cookie settings and Privacy Policy.
Essential Cookies (Required)
These cookies are essential for the website to work properly and can’t be turned off.
They don’t collect personal information.
We also use them to understand how the site is used.
You can choose to block these cookies in your browser, but parts of the site might not work as expected.
Analytics Cookies (Optional)
These cookies help us improve our website and keep content relevant.
We use third-party tools to analyse information gathered by cookies and understand how visitors use our website.
We only use information gathered by cookies internally. See our Privacy Policy.
You can turn these cookies off by clicking "Reject optional cookies", but parts of the site might not work as expected.
Below is a text only representation of the Patient Information Leaflet (ePIL).
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PL 60528/0013.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed only for you or your child. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1. What Deferasirox Umedica is and what it is used for 2. What you need to know before you take Deferasirox Umedica 3. How to take Deferasirox Umedica 4. Possible side effects 5. How to store Deferasirox Umedica 6. Contents of the pack and other information
1. What Deferasirox Umedica is and what it is used for
What Deferasirox Umedica is
Deferasirox Umedica contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools.
What Deferasirox Umedica is used for
Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called iron chelators are used to remove the excess iron and reduce the risk of it causing organ damage.
Deferasirox Umedica is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.
Deferasirox Umedica is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.
Deferasirox Umedica is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.
2. What you need to know before you take Deferasirox Umedica
Do not take Deferasirox Umedica
If you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section 6). If this applies to you, tell your doctor before taking Deferasirox Umedica. If you think you may be allergic, ask your doctor for advice.
If you have moderate or severe kidney disease.
If you are currently taking any other iron chelator medicines.
Deferasirox Umedica is not recommended
If you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer.
Warnings and precautions
Talk to your doctor or pharmacist before taking Deferasirox Umedica:
If you have a kidney or liver problem.
If you have a cardiac problem due to iron overload.
If you notice a marked decrease in your urine output (sign of kidney problem).
If you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction, see also section 4 “Possible side effects”).
If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction, see also section 4 “Possible side effects”).
If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems).
If you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems, see also section 4 “Possible side effects”).
If you vomit blood and/or have black stools.
If you experience frequent abdominal pain, particularly after eating or taking Deferasirox Umedica.
If you experience frequent heartburn.
If you have a low level of platelets or white blood cells in your blood test.
If you have blurred vision
If you have diarrhoea or vomiting.
If any of these apply to you, tell your doctor straight away.
Monitoring your Deferasirox Umedica treatment
You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well Deferasirox Umedica is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). Your doctor may require you to undergo a kidney biopsy, if he/she suspects significant kidney damage. You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of Deferasirox Umedica most suitable for you and will also use these tests to decide when you should stop taking Deferasirox Umedica.
Your eyesight and hearing will be tested each year during treatment as a precautionary measure.
Other medicines and Deferasirox Umedica
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:
other iron chelators, which must not be taken with Deferasirox Umedica,
antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as Deferasirox Umedica,
ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis),
simvastatin (used to lower cholesterol),
certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids),
oral bisphosphonates (used to treat osteoporosis),
anticoagulant medicines (used to prevent or treat blood clotting),
hormonal contraceptive agents (birth control medicines),
bepridil, ergotamine (used for heart problems and migraines),
repaglinide (used to treat diabetes),
rifampicin (used to treat tuberculosis),
phenytoin, phenobarbital, carbamazepine (used to treat epilepsy),
ritonavir (used in the treatment of HIV infection),
paclitaxel (used in cancer treatment),
theophylline (used to treat respiratory diseases such as asthma),
clozapine (used to treat psychiatric disorders such as schizophrenia),
tizanidine (used as a muscle relaxant),
cholestyramine (used to lower cholesterol levels in the blood),
busulfan (used as a treatment prior to transplantation in order to destroy the original bone marrow before the transplant),
midazolam (used to relieve anxiety and/or trouble sleeping).
Additional tests may be required to monitor the blood levels of some of these medicines.
Older people (age 65 years and over)
Deferasirox Umedica can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients. They should be monitored closely by their doctor for side effects that may require a dose adjustment.
Children and adolescents
Deferasirox Umedica can be used in children and adolescents receiving regular blood transfusions aged 2 years and over and in children and adolescents not receiving regular blood transfusions aged 10 years and over. As the patient grows the doctor will adjust the dose.
Deferasirox Umedica is not recommended for children aged under 2 years.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Deferasirox Umedica is not recommended during pregnancy unless clearly necessary.
If you are currently using a hormonal contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom), as Deferasirox Umedica may reduce the effectiveness of hormonal contraceptives.
Breast-feeding is not recommended during treatment with Deferasirox Umedica.
Driving and using machines
If you feel dizzy after taking Deferasirox Umedica, do not drive or operate any tools or machines until you are feeling normal again.
Deferasirox Umedica contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium free’.
3. How to take Deferasirox Umedica
Treatment with Deferasirox Umedica will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How much Deferasirox Umedica to take
The dose of Deferasirox Umedica is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.
The usual daily dose for Deferasirox Umedica film-coated tablets at the start of the treatment for patients receiving regular blood transfusions is 14 mg per kilogram body weight. A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.
The usual daily dose for Deferasirox Umedica film-coated tablets at the start of the treatment for patients not receiving regular blood transfusions is 7 mg per kilogram body weight.
Depending on how you respond to treatment, your doctor may later adjust your treatment to a higher or lower dose.
The maximum recommended daily dose for Deferasirox Umedica film-coated tablets is:
28 mg per kilogram body weight for patients receiving regular blood transfusions,
14 mg per kilogram body weight for adult patients not receiving regular blood transfusions,
7 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.
In some countries, deferasirox may also be available as dispersible tablets, made by other manufacturers. If you are switching from such dispersible tablets to Deferasirox Umedica film-coated tablets, your dose will change. Your doctor will calculate the dose you need and tell you how many film-coated tablets to take each day.
When to take Deferasirox Umedica
Take this medicine once a day, every day, at about the same time each day with some water.
Take Deferasirox Umedica film-coated tablets either on an empty stomach or with a light meal.
Taking this medicine at the same time each day will also help you remember when to take your tablets.
For patients who are unable to swallow whole tablets, Deferasirox Umedica film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple). The food should be immediately and completely consumed. Do not store it for future use.
How long to take Deferasirox Umedica
Continue taking Deferasirox Umedica every day for as long as your doctor tells you. This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect (see also section 2: “Monitoring your Deferasirox Umedica treatment”).
If you have questions about how long to take Deferasirox Umedica, talk to your doctor.
If you take more Deferasirox Umedica than you should
If you have taken too much Deferasirox Umedica, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show the doctor the pack of tablets. Urgent medical treatment may be necessary. You may experience effects such as abdominal pain, diarrhoea, nausea and vomiting and kidney or liver problems that can be serious.
If you forget to take Deferasirox Umedica
If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s).
If you stop taking Deferasirox Umedica
Do not stop taking Deferasirox Umedica unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section “How long to take Deferasirox Umedica”).
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.
Some side effects could be serious and need immediate medical attention.
These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people).
If you get a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction),
If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes, (signs of severe skin reactions),
If you notice a marked decrease in your urine output (sign of kidney problem),
If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems),
If you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems and lead to a change in your brain function),
If you vomit blood and/or have black stools,
If you experience frequent abdominal pain, particularly after eating or taking Deferasirox Umedica,
If you experience frequent heartburn,
If you experience partial loss of vision,
If you experience severe upper stomach pain (pancreatitis),
Stop taking this medicine and tell your doctor straight away.
Some side effects could become serious.
These side effects are uncommon.
If you get blurred or cloudy eyesight,
If you get reduced hearing,
Tell your doctor as soon as possible.
Other side effects
Very common (may affect more than 1 in 10 people)
Disturbance in kidney function tests.
Common (may affect up to 1 in 10 people)
Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating, constipation, indigestion
Rash
Headache
Disturbance in liver function tests
Itching
Disturbance in urine test (protein in the urine)
If any of these affects you severely, tell your doctor.
Uncommon (may affect up to 1 in 100 people)
Dizziness
Fever
Sore throat
Swelling of arms or legs
Change in the colour of the skin
Anxiety
Sleep disorder
Tiredness
If any of these affects you severely, tell your doctor.
Frequency not known (cannot be estimated from the available data).
A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated), in the number of white blood cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)
Hair loss
Kidney stones
Low urine output
Tear in stomach or intestine wall that can be painful and cause nausea
Severe upper stomach pain (pancreatitis)
Abnormal level of acid in blood
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Deferasirox Umedica
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month.
Do not use any pack that is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
This medicinal product does not require any special storage conditions.
6. Contents of the pack and other information
What Deferasirox Umedica contains
The active substance is deferasirox.
Each film-coated tablet of Deferasirox Umedica 90 mg contains 90 mg deferasirox.
Each film-coated tablet of Deferasirox Umedica 180 mg contains 180 mg deferasirox.
Each film-coated tablet of Deferasirox Umedica 360 mg contains 360 mg deferasirox.
The other ingredients are Microcrystalline Cellulose (E460), Crospovidone (E1202), Povidone (E1201), Magnesium stearate and Poloxamer. The film coat consists of Hypromellose (E464), Triacetin (E1518), Titanium dioxide (E171) and Lake Indigo Carmine (E132).
What Deferasirox Umedica looks like and contents of the pack
Deferasirox Umedica is supplied as film-coated tablets. The film-coated tablets are ovaloid and biconvex.
Deferasirox Umedica 90 mg film coated tablet are off white to light blue, ovaloid, about 10.85 x 4.20 mm biconvex film-coated tablets, "90" debossed on one side and "DEF" on other side.
Deferasirox Umedica 180 mg film coated tablet are medium blue, ovaloid, about 14.20 x 5.50 mm biconvex film-coated tablets, "180" debossed on one side and "DEF" on other side.
Deferasirox Umedica 360 mg film coated tablet are dark blue, ovaloid, about 17.40 x 6.86 mm biconvex film-coated tablets, "360" debossed on one side and "DEF" on other side.
The tablets are provided in blister packs containing 30, 60 or 90 film-coated tablets
Not all pack sizes may be marketed.
Marketing Authorization Holder
Umedica Laboratories UK Ltd Office No. G42 The Panorama Park Street Ashford TN24 8DF England
Manufacturer
Elara Pharmaservices Limited 5 Garden Court Lockington Hall Main Street Lockington Derby DE74 2RH United Kingdom
This medicinal product is authorised under the following names: